Opthea

News

Phase 3 readout puts Opthea at risk of insolvency

After its lead wet AMD drug failed a phase 3 trial, Opthea may have to make massive repayments to investors that would threaten its viability.

News

Marea’s $190m double round heads latest biotech financings

Our latest round-up of biotech financings includes nine-figure rounds for Marea, Santa Ana Bio, and Opthea, with InduPro, Elion, and iOnctura also in on the action.

News

RNAi biotech City hauls in $200m in upsized IPO

City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks